Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

Abstract Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort. Methods This is a prospective study conducted in CM patients with a...

Full description

Bibliographic Details
Main Authors: Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Format: Article
Language:English
Published: BMC 2021-10-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Medication overuse
CGRP
Monoclonal antibodies
Erenumab
Galcanezumab
Online Access:https://doi.org/10.1186/s10194-021-01328-1

Similar Items

Similar Items